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Background: Hypertension can be prevented by adopting healthy dietary patterns. Our aim was to assess the
4-year effect on blood pressure (BP) control of a randomized feeding trial promoting the traditional Mediterranean
dietary pattern.
Methods: The PREDIMED primary prevention trial is a randomized, single-blinded, controlled trial conducted in
Spanish primary healthcare centers. We recruited 7,447 men (aged 55 to 80 years) and women (aged 60 to 80
years) who had high risk for cardiovascular disease. Participants were assigned to a control group or to one of two
Mediterranean diets. The control group received education on following a low-fat diet, while the groups on
Mediterranean diets received nutritional education and also free foods; either extra virgin olive oil, or nuts. Trained
personnel measured participants’ BP at baseline and once yearly during a 4-year follow-up. We used generalized
estimating equations to assess the differences between groups during the follow-up.
Results: The percentage of participants with controlled BP increased in all three intervention groups (P-value for
within-group changes: P<0.001). Participants allocated to either of the two Mediterranean diet groups had
significantly lower diastolic BP than the participants in the control group (−1.53 mmHg (95% confidence interval
(CI) −2.01 to −1.04) for the Mediterranean diet supplemented with extra virgin olive oil, and −0.65 mmHg (95%
CI -1.15 to −0.15) mmHg for the Mediterranean diet supplemented with nuts). No between-group differences in
changes of systolic BP were seen.
Conclusions: Both the traditional Mediterranean diet and a low-fat diet exerted beneficial effects on BP and could
be part of advice to patients for controlling BP. However, we found lower values of diastolic BP in the two groups
promoting the Mediterranean diet with extra virgin olive oil or with nuts than in the control group.
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In 2003, the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure estimated that hypertension affects approxi-
mately 1 billion people worldwide [1]. This condition is
a major risk factor for stroke, ischemic heart disease,
and other chronic cardiovascular diseases (CVDs) [2]. In
fact, the relationship between blood pressure (BP) and
risk of CVD events is continuous, consistent, and inde-
pendent of other risk factors [1]. Because of its high
prevalence and its related conditions, hypertension is the
leading individual risk factor for mortality, and is re-
sponsible for 7.6 million deaths per year [3]. Therefore,
from a public heath perspective, approaches to tackle
this condition are needed urgently.
Adopting a healthy lifestyle is a cornerstone of hyper-
tension prevention and treatment, and a healthy diet rep-
resents a major lifestyle modification for BP control [1,4].
High-quality overall dietary patterns, such as the Dietary
Approaches to Stop Hypertension (DASH) diet, can be of
utmost importance in the prevention and treatment of
hypertension [5]. Of these high-quality dietary patterns,
one in particular has received much recent attention be-
cause of the growing evidence for its role in cardiovascular
protection, namely, the traditional Mediterranean diet
(MD) [6]. The MD is a traditional food pattern present in
the olive oil-producing areas of the Mediterranean basin.
Like the DASH diet, the traditional MD is rich in fruits
and vegetables, but it also includes an abundance of le-
gumes, a moderate intake of fish, dairy products, and
wine, small portions of meat and poultry, and little con-
sumption of candies (sweets) [7]. A key characteristic of
this diet is the low amount of animal and trans fatty acids.
Extra virgin olive oil (EVOO), the primary source of fat in
the MD, along with plant foods and nuts, makes this diet
ideal for health because these fresh foods undergo min-
imal processing, so they are rich in fiber, antioxidant poly-
phenols, and essential micronutrients and macronutrients.
Recently, the PREDIMED primary prevention trial showed
that a dietary intervention designed to foster adherence to
the traditional MD significantly reduced the risk of CVD
clinical end-points [8]. The reported reduction in CVD
was most evident for stroke, a condition known to be
highly dependent on BP. Therefore, one mechanism by
which the traditional MD may exert its beneficial effect is
in the control of BP. In fact, a recent meta-analysis
reporting results from clinical studies supported a protect-
ive role for the MD on both systolic and diastolic BP.
However, only two studies had a follow-up time beyond
2 years, and the largest of the two had a sample size of
605 subjects [9].
The aim of this study was to assess the long-term ef-
fect on BP of a dietary intervention to improve adher-
ence to the traditional MD.Methods
Design overview
The PREDIMED (Prevención con Dieta Mediterránea)
study is a multicenter, randomized, parallel-group trial
conducted in Spain (www.predimed.es). A detailed
description of the methods and objectives of the
PREDIMED trial can be found elsewhere [10]. Briefly,
this trial was designed to assess the effects of the trad-
itional MD on the primary prevention of CVD. The
main outcome was an aggregate of non-fatal myocardial
infarction, non-fatal stroke, or cardiovascular death. The
trial was stopped because of early benefit by December
1, 2010 after a median follow-up time of 4.8 years [4].
The current work ascertains the long-term effect of
the dietary interventions on changes in BP during 4
years of follow-up.
Ethics approval
The protocol was written in accordance with the princi-
ples of the Declaration of Helsinki, was approved by
the Institutional Review Boards at all study sites (for
more detailed information, please check Additional file 1),
and was registered at http://www.controlled-trials.com/
ISRCTN35739639. Written informed consent was pro-
vided by all study participants.
Setting and participants
Eligible participants were men (aged 55 to 80 years) and
women (aged 60 to 80 years) who were free of CVD at
study inception but at high cardiovascular risk because
of the presence of either type 2 diabetes (T2D) or at
least three major CVD risk factors, including current
smoking, hypertension, high levels of low-density lipo-
protein cholesterol, low levels of high-density lipoprotein
cholesterol, overweight/obesity, or family history of pre-
mature coronary heart disease (CHD). Further details of
the inclusion and exclusion criteria can be found in our
previously published report [10]. Study candidates were
selected from databases of primary care facilities. Of
those who met entry requirements, 89% agreed to
participate.
At baseline, participants completed a general med-
ical questionnaire, a 137-item previously validated
food-frequency questionnaire [11,12], the Minnesota
Leisure-Time Physical Activity Questionnaire [13,14],
and a 14-item screening questionnaire of adherence to
the traditional MD [15].
Randomization and interventions
During the period October 2003 to June 2009, 7,447 par-
ticipants were enrolled in the study, and randomly allo-
cated in a 1:1:1 ratio by means of a computer-generated
random-number sequence to one of the three intervention
groups: MD supplemented with EVOO (MD+EVOO),
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nuts, almonds, and hazelnuts), or the control diet (low-fat
diet). The coordinating center constructed a computer-
generated randomization table, with allocation conceal-
ment by opaque, sequentially numbered, sealed envelopes.
At baseline and quarterly thereafter, dieticians ran in-
dividual and group sessions, with no more than 20 par-
ticipants, separately for each of the three groups. Group
sessions were specific for each intervention group so
that participants were assessed only for adherence to the
diet to which they had been allocated. In the appropriate
individual sessions, a 14-item dietary screening question-
naire was used to check for adherence to either of the
MDs, and a 9-item dietary screening questionnaire
was used to check for adherence to the control low-fat
diet [15]. The questionnaire responses were used to
personalize the intervention for each participant, and
to negotiate dietary changes to upgrade adherence to
either the MD or the low-fat diet. Participants in the
two intervention groups were given supplementary
foods at no cost: either EVOO (1 liter/week for the
participant and their families) or mixed nuts (30 g/day:
15 g walnuts, 7.5 g hazelnuts, and 7.5 g almonds)
according to their randomization group. Supplementation
of these foods was intended to ensure high consumption
of these key elements of the traditional MD, and to pro-
mote a better overall adherence to the target overall diet-
ary pattern.
The control group received usual care and dietary
counseling (including group sessions) aimed to increase
their adherence to a lower-fat diet. The control group
received non-food items as incentives throughout the
study.
Energy restriction was not specifically advised nor was
physical activity promoted in any of the three groups,
and the interventions did not target sodium intake or
sleep habits. Drugs were prescribed during regular med-
ical care of the participants and were not influenced by
the intervention.
Outcomes and follow-up
At baseline and once yearly thereafter, trained personnel
measured participants’ BP in each arm with a validated
semiautomatic oscillometer (Omron HEM-705CP, Hoofd-
dorp, the Netherlands) at three time points, separated by
2 minutes, while the participant was in a seated position
after 5 minutes of rest. Arm circumference determined
the cuff size, and BP was measured in the forearm at heart
level. The average of the second and third measurement
was recorded in the data collection form.
The mean of the systolic and diastolic BP measure-
ments was also calculated [16,17]. The following
values were considered extreme and were not taken
into account for the analyses: systolic BP <70 mmHgor >260 mmHg, diastolic BP <40 mmHg or >135 mmHg,
systolic BP changes >40 mmHg at 1 year, and diastolic BP
changes >25 mmHg at 1 year.
For the present analysis, we have included information
for 4 years of follow-up (median follow-up time 3.8
years) because the recruitment ended in 2009, and BP
measurements were not available for a substantial num-
ber of participants beyond 4 years.Statistical analysis
Baseline characteristics are presented according to the
intervention group, as mean (SD) for quantitative traits
and n (%) for categorical variables.
All analyses were performed in accordance with an
intention-to-treat approach. First, we assessed differ-
ences in changes in BP between groups during follow-up
[18]. For participants with missing values of BP in the
year 4 visit, we used the most recent available BP infor-
mation. Second, we used generalized estimating equa-
tions to calculate mean differences in systolic and
diastolic BP changes between the groups allocated to the
MD+EVOO or MD+nuts versus the control group in
crude analyses, and after adjustment for center, age, sex
and baseline T2D, and, additionally for baseline number
of anti-hypertensive drugs and baseline systolic or dia-
stolic BP. We assumed an unstructured correlation
matrix and calculated robust variance estimates. Third,
we also used generalized estimating equations to calculate
the percentage of participants with controlled BP levels
(systolic BP <140 mmHg and diastolic BP <90 mmHg)
during follow-up. Fourth, we used generalized estimating
equations to ascertain the number of anti-hypertensive
drugs that were prescribed during follow-up. Analyses
were performed using STATA software (version 11.0;
StataCorp, College Station, TX, USA).Results
Of the 7,447 participants recruited to the PREDIMED
trial, 289 were excluded either because there was no infor-
mation on their baseline BP or they had extreme BP
values. Thus, our effective sample size was 7,158 (Figure 1).
On average, participants had 3.8 visits with available BP
information during follow-up. Specifically, 2,345 partici-
pants in the MD+EVOO group, 2178 participants in the
MD+nuts group, and 2,064 participants in the control
group had BP measurements during follow-up.
In the PREDIMED trial, slightly more women than
men were recruited. Mean age was 67 years. Participants
were at high cardiovascular risk as per protocol, and
they had an average baseline MD score of 8.6 in the 14-
point score of adherence to the MD. All three groups
were well balanced in their baseline characteristics, in-
cluding their dietary and non-dietary traits (Table 1).
Figure 1 Flowchart of participants in the PREDIMED trial.
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were apparent for the three randomized groups during
follow-up (P<0.001 for within-group changes during
follow-up time, adjusted for center, sex, age, and baseline
T2D) (Figure 2). There were no significant between-
group for systolic (P = 0.51 for MD+EVOO versus con-
trol and P>0.99 for MD+nuts versus control) or diastolic
(P = 0.39 for MD+EVOO versus control and P = 0.09
for MD+nuts versus control) BP. These latter compari-
sons were adjusted for center, sex, age, and baseline
T2D.
We found a greater reduction in average systolic BP in
the MD+nuts group than in the control group. However,
between-group differences in systolic BP versus control
with up to 4 years of follow-up were apparent only in
crude analyses, and they became non-significant after
multivariate adjustment. No differences in systolic BP
were found between the MD+EVOO and the control
group (Table 2). However, compared with the control
group, greater reductions in diastolic BP were seen for
both MDs. These differences remained significant in
multivariate-adjusted analyses, with adjusted differences
of −1.53 mmHg (95% CI −2.01 to −1.04) for MD+EVOO
versus control and −0.65 (95% CI −1.15 to −0.15) mmHg
for MD+nuts versus control.
Improvements in BP control were apparent for all
three groups. The percentage of participants who
attained appropriate control of BP levels significantly in-
creased during follow-up time in all the three interven-
tion groups (P<0.001 for time) (Table 3). This beneficial
significant within-group change was maintained afteradjusting for center, age, sex, and baseline T2D. No sig-
nificant between-group differences were seen.
The average number of anti-hypertensive drugs pre-
scribed for the PREDIMED participants significantly in-
creased during follow-up in the three intervention
groups after adjustment for center, sex, age and baseline
T2D. We found no significant between-group differ-
ences. At the end of follow-up, the average number of
BP-lowering drugs in the PREDIMED participants was
1.41 (95% CI 1.36 to 1.46) in the MD+EVOO group,
1.39 (95% CI 1.33 to 1.44) in the MD+nuts group, and
1.39 (95% CI 1.33 to 1.45) in the control group (P>0.99).
Discussion
In this large randomized controlled trial, participants in
all three groups showed improvement in their BP levels,
and, consequently, the percentage of participants with
controlled BP also increased in all three groups. How-
ever, a greater reduction in diastolic BP was obtained
with the MD interventions than with control interven-
tion (advice to follow a low-fat diet). This could partly
explain the recently reported benefit of the MD inter-
vention on clinical disease end-points [8], especially the
reduction in incidence of stroke, a cardiovascular event
clearly related to high BP. However, other mechanisms
apart from BP also need to be taken into account [19].
BP tends to increase with age. Thus, had our partici-
pants not experienced any intervention, they would be
expected to show an increase in their BP levels during
the follow-up period [20]; however, they actually had a
decrease in their BP levels during the intervention. It
Table 1 Baseline characteristics of the PREDIMED trial
participants according to intervention group
Characteristic MD+EVOO,
n = 2441
MD+nuts,
n = 2367
Control diet,
n = 2350
Female sex, n (%) 1424 (58.3) 1275 (53.9) 1402 (59.7)
Age, years 66.9 ± 6.2 66.6 ± 6.1 67.3 ± 6.3
Smoking habit, n (%)
Never-smoker 1505 (61.7) 1414 (59.7) 1462 (62.2)
Former smoker 599 (24.5) 613 (25.9) 561 (23.9)
Current smoker 337 (13.8) 340 (14.4) 327 (13.9)
Body mass indexa 29.9 ± 3.7 29.7 ± 3.8 30.2 ± 4.0
Waist circumference, cm 100 ± 10 100 ± 11 101 ± 11
Hypertension, n (%)b 1999 (81.9) 1951 (82.4) 1972 (83.9)
Systolic BP, mmHg 148 ± 19 149 ± 18 149 ± 19
Diastolic BP, mmHg 83 ± 10 83 ± 10 82 ± 10
Anti-hypertensive therapy, n (%) 1660 (68.0) 1648 (68.4) 1666 (70.9)
Type 2 diabetes, n (%)c 1224 (50.1) 1092 (46.1) 1127 (48.0)
Treatment for type 2 diabetes,
n (%)
801 (32.8) 715 (30.2) 786 (33.5)
Dyslipidemia, n (%)d 1755 (71.9) 1741 (73.6) 1697 (72.2)
Lipid-lowering therapy, n (%) 1095 (44.9) 1041 (44.0) 1032 (43.9)
Family history of premature
CHD, n (%)e
553 (22.7) 514 (21.7) 538 (22.9)
MD adherence scoref 8.7 ± 2.0 8.8 ± 2.0 8.4 ± 2.0
Dietary sodium intake, g/day 2.4 ± 0.9 2.4 ± 0.9 2.3 ± 0.9
Dietary potassium intake, g/day 4.4 ± 1.2 4.4 ± 1.1 4.2 ± 1.1
Dietary calcium intake, g/day 1.1 ± 0.4 1.1 ± 0.4 1.0 ± 0.4
CHD, coronary heart disease; MD+EVOO, Mediterranean diet plus extra virgin
olive oil; MD+nuts, Mediterranean diet plus nuts.
Values are mean ± SD unless otherwise specified.
aBody mass index is the weight in kilograms divided by the square of the
height in meters.
bHypertension was defined as systolic BP ≥140 mm Hg, diastolic BP ≥90 mm
Hg, or use of anti-hypertensive therapy.
cDiabetes was defined as fasting blood glucose ≥126 mg/dl (7.0 mmol/l) on
two occasions, or 2-hour plasma glucose ≥ 200 mg/dl (11.1 mmol/l) after a
75 g oral glucose load, or use of anti-diabetic medication.
dDyslipidemia was defined as low-density lipoprotein cholesterol >160 mg/dl,
high-density lipoprotein cholesterol ≤40 mg/dl in men or ≤50 mg/dl in
women, or use of lipid-lowering therapy.
eA family history of premature CHD was defined as diagnosis of the disease in
a male first-degree relative before the age of 55 years or in a female first-
degree relative before the age of 65 years.
fMedDiet adherence score (minimum adherence = 0 points; maximum
adherence = 14 points).
Figure 2 Adjusted mean systolic and diastolic blood pressure
at baseline and yearly visits according to intervention group.
Values are adjusted for center, sex, age, type 2 diabetes and baseline
blood pressure.
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undergo more evaluations, and thus their doctors are
more likely to prescribe a better adjustment of their
anti-hypertensive medication. However, it should be
noted that the intervention was based only on dietary
changes, and no adjustments in the participants’ regular
prescriptions were part of the intervention. In addition,
participants in the PREDIMED trial were recruited from
their primary healthcare centers, therefore, they werealready attending medical consultations regularly prior
to study entry. In fact, the number of outpatient contacts
in 2004 in Spain was higher than the average in the
European Union [21]. In addition, our participants were
already under medical treatment for their cardiovascular
risk factors.
Current guidelines for the prevention and treatment of
high BP recommend adhering to the DASH diet [22],
which is a healthy eating plan low in saturated fat, chol-
esterol, and in total fat. This diet emphasizes the con-
sumption of fruits, vegetables, and fat-free or low-fat
milk and dairy products [5]. The basic recommendations
provided to our participants in the control group had
Table 2 Mean differences in BP changes (mmHg) in the two intervention groups versus the control group after 4 years
of follow-up (median follow-up 3.8 years)
MD+EVOO versus control P value MD+nuts versus control P value
Systolic BP
Crude model 0.42 (−0.46 to 1.30) 0.35 −0.90 (−1.77 to −0.03) 0.04
Multivariate-adjusted 1a 0.40 (−0.46 to 1.27) 0.36 −0.73 (−1.58 to 0.13) 0.10
Multivariate-adjusted 2b 0.41 (−0.46 to 1.28) 0.35 −0.72 (−1.57 to 0.13) 0.10
Multivariate-adjusted 3c 0.39 (−0.48 to 1.26) 0.38 −0.72 (−1.58 to 0.13) 0.10
Diastolic BP
Crude model −1.41 (−1.92 to −0.91) <0.001 −0.61 (−1.12 to −0.09) 0.02
Multivariate-adjusted 1a −1.49 (−1.98 to −1.00) <0.001 −0.65 (−1.15 to −0.14) 0.01
Multivariate-adjusted 2b −1.49 (−1.97 to −1.00) <0.001 −0.64 (−1.15 to −0.14) 0.01
Multivariate-adjusted 4d −1.53 (−2.01 to −1.04) <0.001 −0.65 (−1.15 to −0.15) 0.01
BP, blood pressure; MD+EVOO, Mediterranean diet plus extra virgin olive oil; MD+nuts, Mediterranean diet plus nuts.
aAdjusted for center, age, sex and diabetes.
bMultivariate-adjusted 1 + additional adjustment for number of baseline anti-hypertensive drugs.
cMultivariate-adjusted 2 + additional adjustment for baseline systolic BP.
dMultivariate-adjusted 2 + additional adjustment for baseline diastolic BP.
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and was not similar to a conventional placebo. There-
fore, it was foreseeable that participants in the control
group would also improve their BP levels if they
followed this advice. In fact, a cohort study with healthy
young participants also conducted in Spain previously
reported an inverse association between adherence to
the DASH diet and incident hypertension [23]. Thus,
had we had a ‘true’ control group (for example, with a
typical Western dietary pattern, or with no intervention
at all) the between-group differences both in stroke and
BP would have been greater. Regarding the intervention
groups, the traditional MD is also rich in fruits and veg-
etables, has low content of saturated fat and dietary
cholesterol, and is rich in magnesium and potassium
[24], thus, in spite of its high total fat content, the MD
could enhance BP control. Even though greater adher-
ence to the MD has shown no association with incident
hypertension in some large cohorts [25], a meta-analysis
of trials with the MD on the components of metabolicTable 3 Percentage of participants with controlled BP levels (
during follow-up in the PREDIMED triala
Intervention
MedDiet+EVOO P valueb MedDiet+nuts
Baseline 33.6 (31.7 to 35.5) – 31.1 (29.3 to 33.0)
Year 1 36.2 (34.2 to 38.2) – 36.9 (34.8 to 39.0)
Year 2 38.6 (36.5 to 40.7) – 40.4 (38.2 to 42.6)
Year 3 37.8 (35.7 to 40.0) – 39.2 (36.8 to 41.5)
Year 4 39.9 (37.4 to 42.3) <0.001 41.5 (38.8 to 44.3)
BP, blood pressure; MD+EVOO, Mediterranean diet plus extra virgin olive oil; MD+n
aAdjusted for center, age, sex and diabetes.
bP-value for within-group changes.
cP-value for between-group changes, after adjustment for multiple comparisons witsyndrome found beneficial effects on average systolic
and diastolic BP levels [9]. Similarly, we found a signifi-
cant decrease in systolic and diastolic BP in both MD
groups. Even though the intervention did not target so-
dium intake, participants in the PREDIMED trial on the
whole did experience a significant reduction in their aver-
age sodium intake, as measured by the semi-quantitative
food-frequency questionnaire. In addition, we found
between-group significant differences (P<0.001) in sodium
reductions favoring the two MD groups. Specifically, par-
ticipants in both intervention (MD) groups experienced
greater sodium reductions than did participants in the
control group. However, these differences are unlikely to
explain the observed results, as 1-year changes in sodium
intake were not significantly associated with 1-year
changes in BP after adjustment for major confounders, in-
cluding the allocation group (data not shown). In addition,
changes in potassium or calcium were also significantly
associated with changes in BP in the multivariate ana-
lyses (data not shown). When we compared the twosystolic BP <140 mmHg and diastolic BP <90 mmHg)
group
P valueb Control P valueb P valuec
– 31.1 (29.2 to 33.0) – NA
– 37.2 (34.9 to 39.4) – >0.99
– 41.4 (38.9 to 43.9) – 0.35
– 39.0 (36.4 to 41.5) – >0.99
<0.001 42.6 (39.5 to 45.7) <0.001 0.69
uts, Mediterranean diet plus nuts; NA, not applicable.
h the Bonferroni method.
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significantly larger decrease in diastolic BP in both MD
groups than in the control (low-fat) group. These results
suggest that the MD may have a greater effect on diastolic
BP control than a low-fat diet. Even though the between-
group differences may seem small, it has been estimated
that small differences in BP may have a large influence on
cardiovascular and total mortality [26]. This influence
needs to be considered within the context of the popula-
tion strategy for preventive medicine [27]. Considering the
strong association between diastolic BP and vascular mor-
tality [28], these results have important clinical relevance
but need to be taken in consideration when explaining the
mechanisms of CVD risk reduction of the MD.
Our results may not seem in perfect agreement with
our previously published results in a small subsample of
PREDIMED participants (our pilot study) after only a 3-
month follow-up. Greater reductions in systolic and dia-
stolic BP were then seen in both MD groups compared
with the control group [29]. There may be several expla-
nations for these differences. First, only the first partici-
pants recruited for the trial were included in the pilot
study. Second, the current work is based on a longer
follow-up than the pilot study, therefore, a different and
longer induction period is assumed. Third, in 2006 the
protocol was reviewed; prior to 2006, no active nutri-
tional education was given to the control group to foster
their adherence to the low-fat diet, and they received
only an information brochure. After the protocol review,
an educational intervention was also devised and
implemented for participants in the control group to
promote the adherence to a low-fat diet with similar
methodology to that of the two MD groups. Fourth, a
higher rate of loss to follow-up occurred in the control
group than in the two MD groups. It is possible that the
participants retained in the control group had a healthier
profile, as suggested by their baseline information [8];
this would selectively bias the results in the control
group towards better BP levels had all participants in
this group been followed up.
The present study has several limitations. First,
changes in BP were a secondary end-point, not the pri-
mary end-point of the PREDIMED trial. Nevertheless,
changes in BP were included in the protocol as a sec-
ondary specific aim from the very beginning of the trial
design. Second, at baseline, a initial fair level of adher-
ence to the MD was present in all participants, regard-
less of their allocated group, and participants in the
control group also maintained their relatively high scores
of adherence to the traditional MD during the study [8].
Therefore, the magnitude of attained between-group dif-
ferences in adherence to the MD during follow-up was
not large. These modest differences can be explained be-
cause for most participants their baseline diet wassimilar to the trial Mediterranean diet. In addition, even
though participants in the control group received advice
to reduce fat intake, changes in total fat were small, and
the largest differences at the end of the trial were in the
distribution of fat subtypes. The good quality of the diet
in the control group may have impaired our ability to
find large between-group differences in BP changes. Not-
withstanding, a significantly better adherence to the pre-
scribed diet was found in the two MD groups than in
the control group, and after the first follow-up year,
mean scores of adherence to the prescribed diet were
significantly higher in the two MD groups than in the
control diet group (P<0.001 for all yearly comparisons
from years 1 to 4 of follow-up). After 3 years of follow-
up we found significantly better scores in both MD
groups than in the control group for 12 of the 14 items
included in the MD adherence screening questionnaire.
Therefore, a modest change in many aspects of the over-
all dietary pattern, and not only in the provided supple-
mental foods, was achieved with our intervention. Third,
information on BP during follow-up was not available
for a subset of participants, especially in the control
group. As has been already published, participants for
whom this information was not available during follow-
up had a worse cardiovascular profile at study inception
than participants who were retained, suggesting a bias
toward a benefit in the control group [8]. Fourth, our
participants lived in a Mediterranean country, had a high
cardiovascular risk, and were mainly hypertensive sub-
jects; all these characteristics may limit the generalizability
of our findings. Fifth, information on anti-hypertensive
drugs dosage was not available, and this precluded a de-
tailed analysis on anti-hypertensive drug usage. However,
because all participants usually attend consultations with
their primary healthcare providers, it is unlikely that par-
ticipants in one or the other group would be differentially
treated.
The strengths of the study include the randomized de-
sign, the long duration of the intervention, the high
compliance of the participants allocated to the MD with
the intended intervention, the large study size, and the
uniformity of study implementation across the different
study sites.Conclusions
In conclusion, our randomized trial conducted in pa-
tients at high risk of CVD supports the traditional MD
supplemented with either EVOO or nuts and the control
diet as having beneficial effects on BP. After 4 years of
follow-up, lower values of diastolic BP were seen in the
two groups that received an intervention with a trad-
itional MD supplemented with either EVOO or with
nuts than in the control group.
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